Stimulant actions in rodents: Implications for attention-deficit/ hyperactivity disorder treatment and potential substance abuse

Biological Psychiatry

Volumn 57, Issue 11, 2005, Pages 1391-1396

  Kuczenski, Ronald ^a   Segal, David S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Attention deficit hyperactivity disorder; Childhood disorders; Methylphenidate; Stimulants; Substance abuse

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; COCAINE; DOPAMINE; METHYLPHENIDATE; NORADRENALIN;

ACCURACY; ATTENTION DEFICIT DISORDER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG SENSITIZATION; HUMAN; LONG TERM EXPOSURE; NONHUMAN; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; RODENT; SUBSTANCE ABUSE;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; METHYLPHENIDATE; NEUROTRANSMITTER AGENTS; RATS; SUBSTANCE-RELATED DISORDERS;

EID: 20444374042     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.12.036     Document Type: Review

References (84)

1. S.L. Andersen, A. Arvanitogiannis, A.M. Pliakas, C. LeBlanc, W.A. Carlezon Jr Altered responsiveness to cocaine in rats exposed to methylphenidate during development Nat Neurosci 5 2002 13 14
2. T. Aoyama, H. Kotaki, T. Iga Dose-dependent kinetics of methylphenidate enantiomers after oral administration of racemic methylphenidate to rats J Pharmacobiodyn 13 1990 647 652
3. T. Aoyama, H. Kotaki, Y. Sawada, T. Iga Pharmacokinetics and pharmacodynamics of methylphenidate enantiomers in rats Psychopharmacol 127 1996 117 122
4. A.F.T. Arnsten Dopaminergic and noradrenergic influences on cognitive functions mediated by prefrontal cortex M.V. Solanto A.F.T. Arnsten F.X. Castellanos Stimulant Drugs and ADHD Basic and Clinical Neuroscience 2001 Oxford University Press New York 185 208
5. R.L. Balster, C.R. Schuster Fixed-interval schedule of cocaine reinforcement Effect of dose and infusion duration J Exp Anal Behav 20 1973 119 129
6. L.Z. Benet, J.R. Mitchell, L.B. Sheiner Pharmacokinetics The dynamics of drug absorption, distribution, and elimination A.G. Gilman T.W. Rall A.S. Nies P. Taylor Goodman and Gilman's The pharmacological basis of therapeutics 8th ed 1990 Pergamon Press New York 3 32
7. C.W. Berridge, T.A. Stalnaker Relationship between low-dose amphetamine-induced arousal and extracellular norepinephrine and dopamine levels within prefrontal cortex Synapse 46 2002 140 149
8. J. Biederman, E. Mick, S.V. Faraone Age-dependent decline of symptoms of attention deficit hyperactivity disorder Impact of remission definition and symptom type Am J Psychiatry 157 2000 816 818
9. J. Biederman, T. Spencer Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder Biol Psychiatry 46 1999 1234 1242
10. C.A. Bolaños, M. Barrot, O. Berton, D. Wallace-Black, E.J. Nestler Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood Biol Psychiatry 54 2003 1317 1329
11. C.L. Brandon, M. Marinelli, L.K. Baker, F.J. White Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats Neuropsychopharmacology 25 2001 651 661
12. C.L. Brandon, M. Marinelli, F.J. White Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons Biol Psychiatry 54 2003 1338 1344
13. C.L. Brandon, H. Steiner Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum Eur J Neurosci 18 2003 1584 1592
14. R.G. Browne, D.S. Segal Metabolic and experiential factors in the behavioral response to repeated amphetamine Pharmacol Biochem Behav 6 1977 545 552
15. F.P. Bymaster, J.S. Katner, D.L. Nelson, S.K. Hemrick-Luecke, P.G. Threlkeld, J.H. Heiligenstein Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat A potential mechanism for efficacy in attention deficit/hyperactivity disorder Neuropsychopharmacology 27 2002 699 711
16. W.A. Carlezon Jr, S.D. Mague, S.L. Andersen Enduring behavioral effects of early exposure to methylphenidate in rats Biol Psychiatry 54 2003 1330 1337
17. N.J. Carrey, D.M. Wiggins, R.P. Milin Pharmacological treatment of psychiatric disorders in children and adolescents Drugs 51 1996 750 759
18. T.D. Challman, J.J. Lipsky Methylphenidate Its pharmacology and uses Mayo Clin Proc 75 2000 711 721
19. T.D. Chase, R.E. Brown, N. Carrey, M. Wilkinson Daily methylphenidate administration attenuates c-fos expression in the striatum of prepubertal rats Neuroreport 14 2003 769 772
20. C.E. Cook, A.R. Jeffcoat, J.M. Hill, D.E. Pugh, P.K. Patetta, B.M. Sadler Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride Drug Metab Dispos 21 1993 17 723
21. C.A. Crawford, S.A. McDougall, T.L. Meier, R.L. Collins, J.B. Watson Repeated methylphenidate treatment induces behavioral sensitization and decreases protein kinase A and dopamine-stimulated adenylyl cyclase activity in the dorsal striatum Psychopharmacology 136 1998 34 43
22. D. Efron, F. Jarman, M. Barker Methylphenidate versus dexamphetamine in children with attention deficit disorder A double-blind, crossover trial Pediatrics 100 1997 e6
23. A.J. Eshleman, K. Wolfrum, D.C. Mash, K. Christensen, A. Janowsky Drug interactions with the dopamine transporter in cryopreserved human caudate J Pharmacol Exp Ther 296 2001 442 449
24. E.J. Garland Pharmacotherapy of adolescent attention deficit hyperactivity disorder Challenges, choices, caveats J Psychopharmacol 12 1998 385 395
25. O. Gaytan, S. Al-Rahim, A. Swann, N. Dafny Sensitization to locomotor effects of methylphenidate in the rat Life Sci 61 1997 PL101 PL107
26. O. Gaytan, C. Lewis, A. Swann, N. Dafny Diurnal differences in amphetamine sensitization Eur J Pharmacol 374 1999 1 9
27. O. Gaytan, P. Yang, A. Swann, N. Dafny Diurnal differences in sensitization to methylphenidate Brain Res 864 2000 24 39
28. M.R. Gerasimov, M. Franceschi, N.D. Volkow, A. Gifford, S.J. Gatley, D. Marsteller Comparison between IP and oral methylphenidate administration A microdialysis and locomotor activity study J Pharmacol Exp Ther 295 2000 51 57
29. L.L. Greenhill Attention-deficit hyperactivity disorder Pediatr Psychopharmacol 4 1995 123 168
30. L.L. Greenhill Clinical effects of stimulant medication in attention-deficit/hyperactivity disorder (ADHD) M.V. Solanto A.F.T. Arnsten F.X. Castellanos Stimulant Drugs and ADHD Basic and Clinical Neuroscience 2001 Oxford University Press New York 31 71
31. T.S. Hale, A.R. Hariri, J.T. McCracken Attention-deficit/hyperactivity disorder Perspectives from neuroimaging Ment Retard Dev Disabil Res Rev 6 2000 214 219
32. S. Izenwasser, A.E. Coy, B. Ladenheim, R.J. Loeloff, J.L. Cadet, D. French Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine Eur J Pharmacol 373 1999 187 193
33. J.I. Javaid, M.N. Musa, M. Fischman, C.R. Schuster, J.M. Davis Kinetics of cocaine in humans after intravenous and intranasal administration Biopharm Drug Dispos 4 1983 9 18
34. H.C. Kimko, J.T. Cross, D.R. Abernethy Pharmacokinetics and clinical effectiveness of methylphenidate Clin Pharmacokinet 37 1999 457 470
35. R. Kuczenski, D.S. Segal Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate Relative roles of dopamine and norepinephrine J Pharmacol Exp Ther 296 2001 876 883
36. R. Kuczenski, D.S. Segal Exposure of adolescent rats to oral methylphenidate Preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine J Neurosci 22 2002 7264 7271
37. G. Laviola, W. Adriani, M. Livia Terranova, G. Gerra Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models Neurosci Biobehav Rev 23 1999 993 1010
38. C.G. McNamara, E.S. Davidson, S. Schenk A comparison of the motor-activating effects of acute and chronic exposure to amphetamine and methylphenidate Pharmacol Biochem Behav 45 1993 729 732
39. M.A. Mehta, A.M. Owen, B.J. Sahakian, N. Mavaddat, J.D. Pickard, T.W. Robbins Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain J Neurosci 20 2000 RC65 NIL13
40. E. Meririnne, A. Kankaanpää, T. Seppälä Rewarding properties of methylphenidate Sensitization by prior exposure to the drug and effects of dopamine D1-and D2-receptor antagonists J Pharmacol Exp Ther 298 2001 539 550
41. D. Michelson, D. Faries, J. Wernicke, D. Kelsey, K. Kendrick, F.R. Sallee Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder A randomized, placebo-controlled, dose-response study Pediatrics 108 2001 NIL33 NIL41
42. G.H. Moll, H. Heinrich, G.E. Trott, S. Wirth, A. Rothenberger Deficient intracortical inhibition in drug-naive children with attention-deficit hyperactivity disorder is enhanced by methylphenidate Neurosci Lett 284 2000 121 125
43. J. Mordenti Man versus beast Pharmcokinetic scaling in mammals J Pharm Sci 75 1986 1028 1040
44. J.A. Morón, A. Brockington, R.A. Wise, B.A. Rocha, B.T. Hope Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter Evidence from knock-out mouse lines J Neurosci 22 2002 389 395
45. National Institutes of Health Consensus Development Conference Statement Diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD) J Am Acad Child Adolesc Psychiatry 39 2001 182 193
46. M.J. Owens, W.N. Morgan, S.J. Plott, C.B. Nemeroff Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites J Pharmacol Exp Ther 283 1997 1305 1322
47. K.S. Patrick, K.R. Ellington, G.R. Breese Distribution of methylphenidate and p-hydroxymethylphenidate in rats J Pharmacol Exp Ther 231 1984 61 65
48. K.S. Patrick, J.S. Markowitz Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder Hum Psychopharmacol 12 1997 527 546
49. W.E. Pelham, E.M. Gnagy, A.M. Chronis, L. Burrows-MacLean, G.A. Fabiano, A.N. Onyango A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder Pediatrics 104 1999 1300 1311
50. T.W. Robbins Chemical neuromodulation of frontal-executive functions in humans and other animals Exp Brain Res 133 2000 130 138
51. T.E. Robinson, J.B. Becker Enduring changes in brain and behavior produced by chronic amphetamine administration A review and evaluation of animal models of amphetamine psychosis Brain Res 11 1986 157 198
52. T.E. Robinson, K.C. Berridge The neural basis of drug craving An incentive-sensitization theory of addiction Brain Res Brain Res Rev 18 1993 247 291
53. D.J. Safer, R.P. Allen Absence of tolerance to the behavioral effects of methylphenidate in hyperactive and inattentive children J Pediatr 115 1989 1003 1008
54. D.J. Safer, J.M. Zito, E.M. Fine Increased methylphenidate usage for attention deficit disorder in the 1990s Pediatrics 98 1996 1084 1088
55. K.W. Sax, S.M. Strakowski Enhanced behavioral response to repeated d-amphetamine and personality traits in humans Biol Psychiatry 44 1998 1192 1195
56. L. Scahill, P.B. Chappell, Y.S. Kim, R.T. Schultz, L. Katsovich, E. Shepherd A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder Am J Psychiatry 158 2001 1067 1074
57. S. Schenk, E. Davidson Stimulant pre-exposure sensitizes rats and humans to the rewarding effects of cocaine NIDA Res Monogr 169 1998 56 82
58. S. Schenk, S. Izenwasser Pretreatment with methylphenidate sensitizes rats to the reinforcing effects of cocaine Pharmacol Biochem Behav 72 2002 651 657
59. D.S. Segal, R. Kuczenski Behavioral pharmacology of amphetamine A.K. Cho D.S. Segal Amphetamine and its analogues Psychopharmacology, toxicology and abuse 1994 Academic Press San Diego 15 150
60. D.S. Segal, A.J. Mandell Long-term administration of d-amphetamine Progressive augmentation of motor activity and stereotypy Pharmacol Biochem Behav 2 1974 249 255
61. D.S. Segal, M.A. Schuckit Animal models of stimulant-induced psychosis I. Creese Stimulants Neurochemical, Behavioral and Clinical Perspectives 1983 Raven Press New York 131 167
62. S.R. Sesack, V.A. Hawrylak, C. Matus, M.A. Guido, A.I. Levey Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter J Neurosci 18 1998 2697 2708
63. S.E. Shaywitz, R.D. Hunt, P. Jatlow, D.J. Cohen, J.G. Young, R.N. Pierce, G.M. Anderson, B.A. Shaywitz Psychopharmacology of attention deficit disorder Pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate Pediatrics 69 1982 688 694
64. M.V. Solanto Clinical psychopharmacology of AD/HD Implications for animal models Neurosci Biobehav Rev 24 2000 27 30
65. E.J. Sproson, J. Chantrey, C. Hollis, C.A. Marsden, K.C.F. Fone Effect of repeated methylphenidate administration on presynaptic dopamine and behaviour in young adult rats J Psychopharmacol 15 2001 67 75
66. N.R. Srinivas, J.W. Hubbard, D. Quinn, K.K. Midha Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder Clin Pharmacol Ther 52 1992 561 568
67. S. Sripada, O. Gaytan, S. Al-Rahim, A. Swann, N. Dafny Dose-related effects of MK-801 on acute and chronic methylphenidate administration Brain Res 814 1998 78 85
68. S.M. Strakowski, K.W. Sax Progressive behavioral response to repeated d-amphetamine challenge Further evidence for sensitization in humans Biol Psychiatry 44 1998 1171 1177
69. S.M. Strakowski, K.W. Sax, H.L. Rosenberg, M.P. DelBello, C.M. Adler Human response to repeated low-dose d-amphetamine Evidence for behavioral enhancement and tolerance Neuropsychopharmacology 25 2001 548 554
70. J.M. Swanson, S. Gupta, D. Guinta, D. Flynn, D. Agler, M. Lerner Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children Clin Pharmacol Ther 66 1999 295 305
71. S.T. Szabo, P. Blier Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons Eur J Neurosci 13 2001 2077 2087
72. G. Tanda, F.E. Pontieri, R. Frau, G. Di Chiara Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine Eur J Neurosci 9 1997 2077 2085
73. F.B. Taylor, J. Russo Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder J Clin Psychopharmacol 21 2001 223 228
74. D.L. Thai, L.N. Yurasits, G.R. Rudolph, J.M. Perel Comparative pharmacokinetics and tissue distribution of the d-enantiomers of para-substituted methylphenidate analogs Drug Metab Dispos 27 1999 645 650
75. L.J.M.J. Vanderschuren, P.W. Kalivas Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization A critical review of preclinical studies Psychopharmacol 151 2000 99 120
76. N.D. Volkow, Y.-S. Ding, J.S. Fowler, G.-J. Wang, J. Logan, S.J. Gatley Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain Arch Gen Psychiatry 52 1995 456 463
77. N.D. Volkow, T.R. Insel What are the long-term effects of methylphenidate treatment? Biol Psychiatry 54 2003 1307 1309
78. N.D. Volkow, G.J. Wang, J.S. Fowler, S.J. Gatley, J. Logan, Y.S. Ding Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate Am J Psychiatry 155 1998 1325 1331
79. W. Wargin, P.C. Kilts, C.T. Gualtieri, K.R. Ellington, R.A. Mueller, G. Kraemer, G.R. Breese Pharmacokinetics of methylphenidate in man, rat and monkey J Pharmacol Exp Ther 226 1983 382 386
80. H.K. Wayment, J.O. Schenk, B.A. Sorg Characterization of extracellular dopamine clearance in the medial prefrontal cortex Role of monoamine uptake and monoamine oxidase inhibition J Neurosci 21 2001 35 44
81. F.J. White, P.W. Kalivas Neuroadaptations involved in amphetamine and cocaine addiction Drug Alcohol Depend 51 1998 141 153
82. T. Wigal, J.M. Swanson, R. Regino, M.A. Lerner, I. Soliman, K. Steinhoff Stimulant medications for the treatment of ADHD Efficacy and limitations Ment Retard Dev Disabil Res Rev 5 1999 215 224
83. P.B. Yang, A.C. Swann, N. Dafny Chronic pretreatment with methylphenidate induces cross-sensitization with amphetamine Life Sci 73 2003 2899 2911
84. J.M. Zito, D.J. Safer, S. dosReis, J.F. Gardner, M. Boles, F. Lynch Trends in the prescribing of psychotropic medications to preschoolers JAMA 283 2000 1025 1030